Institute of Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Institute of Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Curr Probl Cancer. 2019 Oct;43(5):438-442. doi: 10.1016/j.currproblcancer.2018.12.001. Epub 2018 Dec 10.
Alteration of biomarkers is well-documented in breast cancer at locoregional recurrence or metastasis attributed to tumor heterogeneity and change in biology. There is a lack of literature on alteration of biomarkers in metastatic breast cancer (MBC) at progression. We included 32 patients of upfront MBC. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2/neu documented at baseline and at progression. Median age was 46 (range 26-72) years. Estrogen receptor altered in 6 (18.75%) patients [4 (12.5%) positive to negative and 2 (6.25%) from negative to positive], progesterone receptor altered in 8 (25.3%) patients (6 [18.75%] positive to negative and 2 [6.25%] negative to positive) and human epidermal growth factor receptor 2/neu altered in 5 (15.6%) patients (all were positive to negative). Therapy was changed as per new receptor status. Documentation of change in receptor status may be justified to determine further therapy and prognosis in MBC at progression.
在归因于肿瘤异质性和生物学变化的局部区域复发或转移的乳腺癌中，生物标志物的改变已有充分的文献记载。关于转移性乳腺癌（MBC）进展时生物标志物改变的文献很少。我们纳入了 32 例初诊 MBC 患者。在基线和进展时记录了雌激素受体、孕激素受体和人表皮生长因子受体 2/neu。中位年龄为 46 岁（范围 26-72 岁）。6 名患者（18.75%）的雌激素受体发生改变[4 名（12.5%）由阳性转为阴性，2 名（6.25%）由阴性转为阳性]，8 名患者（25.3%）的孕激素受体发生改变[6 名（18.75%）由阳性转为阴性，2 名（6.25%）由阴性转为阳性]，5 名患者（15.6%）的人表皮生长因子受体 2/neu 发生改变（均由阳性转为阴性）。根据新受体状态改变了治疗方案。在 MBC 进展时，记录受体状态的改变可能有助于确定进一步的治疗和预后。
